Aprea Therapeutics Inc. Stock News

Aprea Therapeutics (NASDAQ:APRE) Director Scott M. Rocklage sold 245,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $28.75,

Pendleton was hired in April to replace Jim Zalesky

The line of credit, issued through Goldman Sach's Marcus bank brand, will include an APR starting at 6.99% on a credit line of up to $1 million.

In this article we will check out the progression of hedge fund sentiment towards Aprea Therapeutics, Inc. (NASDAQ:APRE) and determine whether it is a good investment right now. We at Insider Monkey l

Aprea Therapeutics, Inc. (APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced

Aprea Therapeutics (APRE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Torrini’s championing of the 62-year-old Phantom jet-still flown by several air forces-sprang from a conviction that the old and powerful could remain new and vibrant with a little thoughtful evolut

Transferring a credit card balance is easy.

Here's why this biotech company with a promising treatment for a rare blood disorder is a solid buy.

Drivelectric Kenya, a subsidiary of Knights Energy Kenya, is offering Kenyans a platform to switch to electromobility. Driveelectric Kenya’s suite of services is tailored to take away the risks (bot

The job losses induced by COVID-19 are a catastrophic development for millions of Americans who could least afford it. Between skyrocketing healthcare costs, a lack of safety net...